

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

**Durvalumab with tremelimumab for untreated advanced or unresectable
hepatocellular carcinoma [ID2725]**

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AstraZeneca (durvalumab, tremelimumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addenbrookes Liver Transplant Association • Black Health Agency for Equality • British Liver Trust • Cancer Black Care • Cancer Equality • Cancer 52 • GUTS UK • Haemochromatosis UK • Helen Rollason Cancer Charity • Independent Cancer Patients' Voice • Liver4Life • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Pelican Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • The Hepatitis C Trust <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists of Great Britain & Ireland • Association of Cancer Physicians • Association of Surgeons of Great Britain & Ireland • British Association of the Study of the Liver (BASL) / HCC UK • British Geriatrics Society • British Institute of Radiologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Bayer (sorafenib) • Boston Scientific (TheraSphere) • Celltrion Healthcare (bevacizumab) • Dr. Reddy's Laboratories (bevacizumab) • Eisai (lenvatinib) • Organon Pharma (bevacizumab) • Pfizer (bevacizumab) • Roche (atezolizumab, bevacizumab) • Sandoz (sorafenib) • Sirtex (SIR-Spheres) • Terumo Europe (QuirumSpheres) • Thornton and Ross (bevacizumab, sorafenib)

Final stakeholder list for the appraisal of durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

Issue date: June 2024

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Oncology Pharmacy Association • British Psychosocial Oncology Society • British Society of Gastroenterology • Cancer Research UK • Hepatitis Nurse Specialist Forum • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiologists • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Zentiva (bevacizumab, sorafenib) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-biliary Group • Cochrane Infectious Diseases Group • Cochrane UK • Foundation for Liver Research • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme (NETSCC) • Warwick Evidence <p><u>Associated Guideline Group</u></p> <ul style="list-style-type: none"> • NICE - National Guideline Alliance (cancer, mental health, and women and children's health)

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.